Novartis signs two major licensing deals
|
DEALS |
|||
|
WHO |
WITH |
WHAT |
SCOOP |
|
Novartis |
Human Genome Sciences |
$552.2M licensing deal |
Novartis has licensed HGS's hepatitis C drug Albuferon for an upfront payment of $45 million and milestones of up to $507.5 million for the development of the therapy. |
|
Novartis |
Cytopia |
$274 licensing deal |
Novartis will pay Cytopia $13M in up front fees as part of a $274M package that includes major milestones on new therapies to prevent transplant rejection and to treat auto-immune diseases. |
|
AnGes |
Vical |
$100M licensing deal |
Japan's AnGes has agreed to pay up to $100 million in research funding and milestone fees in a licensing deal for Vical's Allovectin-7 cancer therapy. |
|
BioLineRx |
Gevys Pharmaceuticals |
Licensing deal |
The deal is for worldwide rights to Gevys Pharmaceuticals' experimental pain drug BL-3010. |
|
Novartis |
NeuTec Pharma |
$569M acquisition |
Novartis has bid $569 million to acquire NeuTec Pharma, a British drug developer with several late-stage candidates in the pipeline. NeuTec's board has backed the takeover. |
|
Covance |
Signet Laboratories |
$8.95M asset acquisition |
Covance has acquired most of the assets of Signet Laboratories for $8.95 million. |
|
Biogen Idec |
Fumapharm |
Acquisition |
The companies will continue to collaborate BG-12 for MS and psoriasis and Biogen Idec will expand its European operations. |
|
PerkinElmer |
Clinical & Analytical Service Solutions |
Acquisition |
PerkinElmer has acquired Clinical & Analytical Service Solutions for an undisclosed sum. |
|
Gilead Sciences |
Raylo Chemicals |
$147.8M buyout |
Gilead says it needs Raylo, a subsidiary of Germany's Degussa, for its experience as a chemical and manufacturing experience. |
|
Angiotech Pharmaceuticals |
Quill Medical |
$40M buyout |
Quill Medical makes the Contour Threads surgical suture product. |
|
Bristol-Myers Squibb |
Lexicon Genetics |
$20M alliance |
Bristol-Myers Squibb has extended its alliance with Lexicon Genetics on psychiatry and neurology therapies by two years, adding another $20 million in new research funds. |
|
Parata Systems |
McKesson' |
Sale |
Parata Systems has inked a deal to buy virtually all of the assets in McKesson's automated prescriptions systems division. McKesson becomes Parata's sole third-party distributor in the U.S. |
|
CombinatoRx |
Cystic Fibrosis Foundation Therapeutics |
$13.8M collaboration |
The companies will collaborate to find new drug combination therapies for cystic fibrosis. |
|
Highland Clan |
Raptor Pharmaceutical |
Reverse takeover |
Raptor will become a wholly owned subsidiary of Highland and Highland will focus solely on the development of Raptor's RAP technology. |